🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06672432
Starting soon Not applicable

Preventing Perinatal Depression with an App-Based CBT Program

NCT06672432 · tracked via the Priya Life Science China tracker
Sponsor
Jintang County Maternal and Child Health Hospital
Phase
Not applicable
Started
2024-11
Last updated
2024-11-04

Condition(s) studied

Perinatal DepressionDisease Prevention

Investigational drug(s) / intervention(s)

CareMom (a mobile app-based 8-wekk cognitive behavioral therapy program)Matched Attention Control (a mobile app-based 8-week online relaxation training program)

CareMom (a mobile app-based 8-wekk cognitive behavioral therapy program): The intervention is divided into daily tasks spread across eight weeks, with each day involving a variety of interactive elements such as videos, text-based content, guided reflections, and mental health check-ins. If the user misses a daily challenge, she can complete that challenge in the later days. Each week has a distinct focus that progressively builds the user's skills and understanding in managing emotional health. Tasks are designed to be short yet impactful, aiming to enhance engagement and adherence.

Matched Attention Control (a mobile app-based 8-week online relaxation training program): This program is designed to mirror the structure and engagement level of the intervention group, providing participants with a similar amount of interaction and daily activities. Each day, participants in the control group will complete 1-2 daily tasks focused on relaxation techniques, such as breathing exercises, mindfulness meditation, and guided imagery. Each task is brief, approximately 3 minutes in duration, making it easy for participants to incorporate into their daily routine.

Study summary

The goal of this clinical trial is to learn if CareMom, a mobile app-based cognitive behavioral therapy program works to prevent perinatal depression among Chinese mothers. The main questions the trial aims to answer are:

1. Does CareMom lower depression scores after an 8-week intervention?
2. Does CareMom lower depression scores at 6 weeks after childbirth?
3. How satisfied are participants with CareMom?
4. What unfavorable events, if any, are associated with the use of CareMom?

Researchers will compare CareMom to a matched attention control (a mobile app-based program that offers participants a similar level of interaction and daily activities) to see if CareMom works to prevent perinatal depression.

Participants will:

1. Engage in the CareMom program or a relaxation training program every day for 8 weeks
2. Complete a series of online questionnaire tests before and after the 8-week intervention.
3. Report any discomfort experienced throughout the study period.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * aged 18-45 years * at 20-24 weeks of gestation * at risk of depression but not experiencing severe depressive symptoms at recruitment, as indicated by an Edinburgh Postnatal Depression Scale (EPDS) score of between 5 and 12 * own a smartphone * are able to independently engage with the program Exclusion Criteria: * have serious medical conditions or pregnancy complications that may affect their psychological condition, as determined by their medical doctor * have a prior diagnosis of any mental disorders * are currently or were recently (within the past six months) receiving any kinds of psychological services or treatments * have a history of self-harm or suicide * have any suicidal thoughts in the past 12 months * experienced fetal deaths in the past 18 months

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Jintang County Maternity and Child Health Hospital Chengdu Sichuan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06672432 on ClinicalTrials.gov ↗ ← All trials in China